dedicator of cytokinesis 3Genealiases: MOCA · NEDIDHA · PBP
Q-omics provides the consensus-scored DOCK3 profile across patient tissues and cancer cell-line models. DOCK3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DOCK3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, DOCK3 protein abundance shows 23,825 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where DOCK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOCK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOCK3 survival associations across molecular data types. DOCK3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOCK3 RNA expression–survival associations across cancer types. High DOCK3 expression shows unfavorable associations in STAD, KIRC, UCEC and COAD, but favorable associations in ACC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DOCK3 RNA expression.
This table summarizes DOCK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DOCK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOCK3 shows lower tumor expression in KIRC, HNSC and STAD and higher tumor expression in LUAD, KICH and LIHC. The KIRC box plot shows higher DOCK3 RNA expression in normal versus tumor tissue (log2 FC = −0.668, t-test p < 0.001).
This table shows molecular features associated with DOCK3 in patient tissues and cancer cell lines. In patient samples, DOCK3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DOCK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and OVARY.
